Article
RNA editing with CRISPR-Cas13
25 Oct 2017
Abstract excerpt
Nucleic acid editing holds promise for treating genetic disease, particularly at the RNA level, where disease-relevant sequences can be rescued to yield functional protein products. Type VI CRISPR-Cas systems contain the programmable single-effector RNA-guided ribonuclease Cas13. We profiled type VI systems in order to engineer a Cas13 ortholog capable of robust knockdown and demonstrated RNA editing by using...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
